A combination therapy product for treatment of patients having cisplatin-resistant cancer.
- Identified the use of MAST1 inhibitors (such as lestaurtinib) to target cisplatin-resistant cancer.
- Lestaurtinib sensitized cells to cisplatin treatment the most using a concentration that attenuates cell viability by less than 20% when treated alone.
The global cancer therapy market was valued at approximately $128.1 billion in 2018 and is expected to grow to $182 billion by 2023 with a CAGR of 7.3% from 2018-2023 (BCC Research PHM177B). The described targeting of MAST1-MEK1 is not tumor-specific, suggesting the method could be applied across various cancer types. However, data in this disclosure specifically relate to head and neck, lung, and ovarian cancer cells. Head and neck, lung, and ovarian cancers account for 63,030, 222,500, and 22,440 (women), respectively, of cancer diagnosis.
Researchers at Emory have developed a combination therapy product for the treatment of patients diagnosed with cisplatin-resistant cancer. The researchers identified microtubule-associated serine/threonine kinase 1 (MAST1) through a kinome RNAi screen as a main driver of cisplatin resistance in various human cancers. By targeting MAST1 with the newly identified MAST1 inhibitor (lestaurtinib) the researchers were able to restore cisplatin sensitivity in human cancer cells in vitro and in vivo, thus leading to the synergistic reduction of cancer cell proliferation and tumor growth in human cancer cells as well as patient-derived xenograft models.
TTO Home Page: https://emoryott.technologypublisher.com
Name: Hyeon (Sean) Kim
Title: Licensing Associate